Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;53(12):e2350446.
doi: 10.1002/eji.202350446. Epub 2023 Oct 27.

SHIP1 and its role for innate immune regulation-Novel targets for immunotherapy

Wen Jie Yeoh  1   2 , Philippe Krebs  1
Affiliations
Free article
Review

SHIP1 and its role for innate immune regulation-Novel targets for immunotherapy

Wen Jie Yeoh et al. Eur J Immunol. 2023 Dec.
Free article

Abstract

Phosphoinositide-3-kinase/AKT (PI3K/AKT) signaling plays key roles in the regulation of cellular activity in both health and disease. In immune cells, this PI3K/AKT pathway is critically regulated by the phosphoinositide phosphatase SHIP1, which has been reported to modulate the function of most immune subsets. In this review, we summarize our current knowledge of SHIP1 with a focus on innate immune cells, where we reflect on the most pertinent aspects described in the current literature. We also present several small-molecule agonists and antagonists of SHIP1 developed over the last two decades, which have led to improved outcomes in several preclinical models of disease. We outline these promising findings and put them in relation to human diseases with unmet medical needs, where we discuss the most attractive targets for immune therapies based on SHIP1 modulation.

Keywords: Immunoregulation; Immunotherapy; Innate immunity; SHIP1; Therapeutics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C. and Abraham, R. T., The PI3K pathway in human disease. Cell. 2017. 170: 605-635.
    1. Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y. and Wei, X., Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol. Cancer 2019. 18: 26.
    1. Saxton, T. M., van Oostveen, I., Bowtell, D., Aebersold, R. and Gold, M. R., B cell antigen receptor cross-linking induces phosphorylation of the p21ras oncoprotein activators SHC and mSOS1 as well as assembly of complexes containing SHC, GRB-2, mSOS1, and a 145-kDa tyrosine-phosphorylated protein. J. Immunol. 1994. 153: 623-636.
    1. Pauls, S. D. and Marshall, A. J., Regulation of immune cell signaling by SHIP1: a phosphatase, scaffold protein, and potential therapeutic target. Eur. J. Immunol. 2017. 47: 932-945.
    1. Pedicone, C., Meyer, S. T., Chisholm, J. D. and Kerr, W. G., Targeting SHIP1 and SHIP2 in cancer. Cancers (Basel) 2021. 13: 890.

Publication types

MeSH terms

Substances